Search Results for "opioids"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for opioids. Results 11 to 20 of 62 total matches.
Zavegepant (Zavzpret) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
. Use
of opioid- or butalbital-containing products for
migraine treatment is not recommended.3,5,6 ...
The FDA has approved zavegepant nasal spray
(Zavzpret – Pfizer) for acute treatment of migraine
with or without aura in adults. Zavzpret is the first
nasal spray formulation of a calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant") to
become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8 doi:10.58347/tml.2023.1681c | Show Introduction Hide Introduction
Table: Some Drug Interactions with Drugs for IBD (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
opioids) or noradrenergic drugs with ozanimod could result in hypertensive crisis and is not recommended ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114 doi:10.58347/tml.2023.1680c | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
or an opioid are
not recommended for acute treatment of migraine.
There is limited evidence that butalbital ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
and for opioid-induced constipation in adults with chronic noncancer pain.
5. The recommended dosage is 16 mcg ...
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who have
not experienced relief of their bowel symptoms
by using laxative therapies at the recommended
dosage for at least one month. It is the first drug-free
treatment to be authorized by the FDA for this
indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7 doi:10.58347/tml.2023.1675a | Show Introduction Hide Introduction
In Brief: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
)
sale of Narcan (Emergent), a nasal spray that delivers
4 mg of the opioid antagonist naloxone. Narcan ...
The FDA has approved the over-the-counter (OTC)
sale of Narcan (Emergent), a nasal spray that delivers
4 mg of the opioid antagonist naloxone. Narcan nasal
spray has been available by prescription since 2015
for emergency treatment of opioid overdose. Generic
formulations of Narcan have also been approved; the
manufacturers of these products will be required to
switch them to OTC status and amend their labeling
accordingly. Kloxxado, an 8-mg naloxone nasal
spray, remains available only by prescription.
Med Lett Drugs Ther. 2023 May 1;65(1675):72 doi:10.58347/tml.2023.1675e | Show Introduction Hide Introduction
Drugs for Chronic Insomnia
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
or other CNS depressants is not recommended.
Concurrent use of an opioid and a benzodiazepine ...
Cognitive behavioral therapy for insomnia (CBT-I) is
recommended for initial treatment of chronic insomnia.
CBT-I includes stimulus control, sleep education
and hygiene, sleep restriction, relaxation training, and
cognitive therapy. When CBT-I alone is not effective,
pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6 doi:10.58347/tml.2023.1667a | Show Introduction Hide Introduction
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
, are elderly, or are receiving opioids or other CNS or cardiorespiratory depressants.
3. Approximate WAC ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10 doi:10.58347/tml.2023.1667b | Show Introduction Hide Introduction
Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
,
sedatives, hypnotics, or opioids can result in
enhanced CNS depressant effects; a reduction in the
dose ...
The FDA has approved a sublingual film formulation
of the alpha-2 adrenergic receptor agonist
dexmedetomidine (Igalmi — BioXcel Therapeutics)
for acute treatment of agitation associated with
schizophrenia or bipolar I or II disorder in adults. It is
the first alpha-2 agonist and the only sublingual film
to be approved for this indication. Dexmedetomidine
has been available for many years in an injectable
formulation (Precedex) for sedation in the intensive
care unit and to facilitate procedures such as
mechanical ventilation.
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
(Contrave) is
approved for weight management.
PHARMACOLOGY — Dextromethorphan is an analog
of the opioid ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
Opioids for Pain ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.